SCHEMBL3527401

SCHEMBL3527401

Cc1nc(O)c(Br)c(=O)n1Cc1cccc(F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
PDE1A P54750 1/20 0.49
PDE1B Q01064 1/20 0.49
PDE1C Q14123 1/20 0.49
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
PKM P14618 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CASR P41180 2/20 0.47
IDO1 P14902 2/20 0.45
POLB P06746 2/20 0.45
GRIN1 Q05586 1/20 0.45
GRIN2B Q13224 1/20 0.45
LMNA P02545 1/20 0.45
GLA P06280 1/20 0.45
PCSK9 Q8NBP7 1/20 0.43
MAPT P10636 3/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519568 0.82 MEN1 (0.52) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL4379494 0.81 KDM4E (0.58) PDE1APDE1BPDE1CKDM4EALDH1A1
SCHEMBL3520927 0.79 MEN1 (0.50) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL3521516 0.78 MEN1 (0.48) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL3524971 0.75 MAPK14 (0.53) PDE1APDE1BPDE1CKDM4EALDH1A1
SCHEMBL4376208 0.74 KDM4E (0.54) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL31196717 0.74 MEN1 (0.71) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL13610864 0.72 KDM4E (0.55) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL3522069 0.72 MAPK14 (0.58)
SCHEMBL16043364 0.72 GALR3 (0.54) MEN1KMT2APOLBLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795271-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2010-09-14 US disclosed
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES PFIZER INC 2009-12-10 US disclosed
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES PHARMACIA CORPORATION (US) 2007-07-19 US disclosed
US-7183287-B2 Substituted pyrimidinones PHARMACIA CORPORATION (US) 2007-02-27 US disclosed
US-20040242608-A1 Substituted pyrimidinones PHARMACIA LLC 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306108-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 MEN1 3915/4885KMT2A 3940/4885PDE1A 1355/4885
US-20040242608-A1 Substituted pyrimidinones MAPK1, MAPK7, MAP3K8 MEN1 4074/4885KMT2A 4243/4885PDE1A 1492/4885
US-20070167621-A1 SUBSTITUTED PYRIMIDINONES MAPK1, MAP3K8, MAP3K7 MEN1 3915/4885KMT2A 3940/4885PDE1A 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.